Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 360° synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Growing prevalence of hemophilia across the globe
3.2.1.2 Rise in favorable government initiatives
3.2.1.3 Increase in R&D and new product development
3.2.1.4 Growing adoption of prophylaxis treatment
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost associated with hemophilia treatment
3.2.2.2 Lack of awareness in developing and under-developed regions
3.2.2.3 Low adoption rates of technologically advanced products
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Pipeline analysis
3.7 Porter’s analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Disease Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Hemophilia A
5.2.1 Severe
5.2.2 Moderate
5.2.3 Mild
5.3 Hemophilia B
5.3.1 Severe
5.3.2 Moderate
5.3.3 Mild
5.4 Other disease types
Chapter 6 Market Estimates and Forecast, By Product, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Recombinant coagulation factor concentrates
6.2.1 Factor VIII
6.2.2 Factor IX
6.3 Plasma-derived coagulation factor concentrates
6.3.1 Factor VIII
6.3.2 Factor IX
6.4 Extended half-life products
6.4.1 Factor VIII
6.4.2 Factor IX
6.5 Desmopressin
6.6 Antifibrinolytic agents
6.7 Gene therapy products
Chapter 7 Market Estimates and Forecast, By Patient, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Pediatric
- 7.2.1. 0to 4
- 7.2.2. 5to 13
- 7.2.3. 14to18
7.3 Adult
- 7.3.1. 19to 44
- .7.3.2. 45+
Chapter 8 Market Estimates and Forecast, By Treatment, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Prophylaxis
8.3 On demand
Chapter 9 Market Estimates and Forecast, By Therapy, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 Factor replacement therapy
9.3 Non-factor replacement therapy
Chapter 10 Market Estimates and Forecast, By Drug Class, 2021 – 2032 ($ Mn)
10.1 Key trends
10.2 Vasopressin
10.3 Coagulation factors
Chapter 11 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
11.1 Key trends
11.2 Injectable
11.3 Nasal spray
11.4 Oral
Chapter 12 Market Estimates and Forecast, By End-use, 2021 – 2032 ($ Mn)
12.1 Key trends
12.2 Hospitals
12.3 Clinics
12.4 Hemophilia treatment centers
12.5 Other end-users
Chapter 13 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
13.1 Key trends
13.2 North America
13.2.1 U.S.
13.2.2 Canada
13.3 Europe
13.3.1 Germany
13.3.2 UK
13.3.3 France
13.3.4 Spain
13.3.5 Italy
13.3.6 Netherlands
13.3.7 Rest of Europe
13.4 Asia Pacific
13.4.1 China
13.4.2 Japan
13.4.3 India
13.4.4 Australia
13.4.5 South Korea
13.4.6 Rest of Asia Pacific
13.5 Latin America
13.5.1 Brazil
13.5.2 Mexico
13.5.3 Rest of Latin America
13.6 Middle East and Africa
13.6.1 South Africa
13.6.2 Saudi Arabia
13.6.3 UAE
13.6.4 Rest of Middle East and Africa
Chapter 14 Company Profiles
14.1 Bayer AG
14.2 Biogen Inc.
14.3 Biotest AG (Grifols, S.A.)
14.4 BioMarin Pharmaceutical Inc
14.5 CSL Behring LLC
14.6 Ferring B.V.
14.7 Genentech, Inc. (Roche Holding AG)
14.8 Kedrion S.p.A
14.9 Novo Nordisk A/S
14.10 Octapharma AG
14.11 Pfizer, Inc.
14.12 Sanofi SA
14.13 Swedish Orphan Biovitrum AB
14.14 Takeda Pharmaceutical Company Limited
Hemophilia Treatment Market Analysis
Based on disease type, the market is segmented as hemophilia A, hemophilia B, and other disease types. Hemophilia A disease segment dominated the market in 2023 accounting for USD 10.2 billion.
Based on product, the hemophilia treatment market is segmented into recombinant coagulation factor concentrates, plasma-derived coagulation factor concentrates, extended half-life products, desmopressin, antifibrinolytic agents, and gene therapy products. The recombinant coagulation factor concentrates segment is further divided into factor VIII and factor IX. The recombinant coagulation factor concentrates segment dominated the market in 2023 with a market share of 58.2%.
Based on patient, the hemophilia treatment market is segmented into pediatric and adult. The adult segment is further segmented into 19 to 44 and 45+ age group The adult segment is anticipated to grow at a CAR of 5.5% over the forecast years.
Based on treatment, the hemophilia treatment market is segmented into prophylaxis and on demand. The prophylaxis segment dominated the market in 2023 and is anticipated to reach USD 15.1 billion by 2032.
Based on therapy, the hemophilia treatment market is segmented into factor replacement therapy and non-factor replacement therapy. The factor replacement therapy segment dominated the market in 2023 and is anticipated to grow at a CAGR of 5.5% over the analysis timeframe.
Based on drug class, the hemophilia treatment market is categorized into vasopressin and coagulation factors. The coagulation factors segment held a market share of 94.7% in 2023.
Based on route of administration, the hemophilia treatment market is categorized into injectable, nasal spray, and oral. The injectable segment is anticipated to witness significant growth to reach USD 18.4 billion by 2023.
Based on end-use, the hemophilia treatment market is segmented into hospitals, clinics, hemophilia treatment centers, and other end-users. The hospitals segment dominated the market in 2023 and is anticipated to grow at a CAGR of 5.8% between 2024 - 2032.
North America hemophilia treatment market was valued at USD 5.8 billion in 2023 and is anticipated to reach USD 9.1 billion by 2032.
U.S. hemophilia treatment market is anticipated to grow at a CAGR of 5.1% between 2024 - 2032.
Germany is anticipated to witness robust growth in the global hemophilia treatment market.
Asia Pacific region will exhibit high growth over the forecast period.
On-demand Wellness Software Market
Womens Health App Market
Acute Care Telemedicine Market
Digital Therapeutics Market